The current state of acute treatment for migraine in adults in the United States

References

• American Headache Society. The American headache society position statement on integrating new migraine treatments into clinical practice. Headache. 2019;59(1):1–18.
   PubMed Web of Science ®Google Scholar
• Headache Classification Committee of the International Headache Society. The international classification of headache disorders, 3rd edition. Cephalalgia. 2018;38(1):1–211.
   PubMed Web of Science ®Google Scholar
• Woldeamanuel YW, Cowan RP. Migraine affects 1 in 10 people worldwide featuring recent rise: A systematic review and meta-analysis of community-based studies involving 6 million participants. J Neurol Sci. 2017;372:307–315.
   PubMed Web of Science ®Google Scholar
• Facts about migraine [Internet]. Mount Royal (NJ): American Migraine Foundation; 2019 [cited 2019 Feb 12]. Available from: https://americanmigrainefoundation.org/wp-content/uploads/2019/03/Facts-About-Migraine-AMF.pdf
   Google Scholar
• Burch R, Rizzoli P, Loder E. The prevalence and impact of migraine and severe headache in the United States: figures and trends from government health studies. Headache. 2018;58(4):496–505.
   PubMed Web of Science ®Google Scholar
• Lipton RB, Silberstein SD. Episodic and chronic migraine headache: breaking down barriers to optimal treatment and prevention. Headache. 2015;55(Suppl 2):103–122; quiz 123–126.
   Google Scholar
• Burton WN, Landy SH, Downs KE, et al. The impact of migraine and the effect of migraine treatment on workplace productivity in the United States and suggestions for future research. Mayo Clin Proc. 2009;84(5):436–445.
   PubMed Web of Science ®Google Scholar
• GBD. 2016 Disease and injury incidence and prevalence collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the global burden of disease study 2016. Lancet. 2017;390(10100):1211–1259.
   PubMed Web of Science ®Google Scholar
• Burch RC, Loder S, Loder E, et al. The prevalence and burden of migraine and severe headache in the United States: updated statistics from government health surveillance studies. Headache. 2015;55(1):21–34.
   PubMed Web of Science ®Google Scholar
• Giamberardino MA, Affaitati G, Costantini R, et al. Acute headache management in emergency department. A narrative review. Intern Emerg Med. 2020;15(1):109–117.
   PubMed Web of Science ®Google Scholar
• Schwartz BS, Stewart WF, Lipton RB. Lost workdays and decreased work effectiveness associated with headache in the workplace. J Occup Environ Med. 1997;39(4):320–327.
   PubMed Web of Science ®Google Scholar
• Schwartz BS, Stewart WF, Simon D, et al. Epidemiology of tension-type headache. JAMA. 1998;279(5):381–383.
   PubMed Web of Science ®Google Scholar
• Navigating life with migraine in the workplace [Internet]. Mount Royal (NJ): American Migraine Foundation; 2019 [cited 2020 Feb 12]. Available from: https://americanmigrainefoundation.org/resource-library/navigating-migraine-in-the-workplace/
   Google Scholar
• Messali A, Sanderson JC, Blumenfeld AM, et al. Direct and indirect costs of chronic and episodic migraine in the United States: a web-based survey. Headache. 2016;56(2):306–322.
   PubMed Web of Science ®Google Scholar
• Raval AD, Shah A. National trends in direct health care expenditures among US adults with migraine: 2004 to 2013. J Pain. 2017;18(1):96–107.
   PubMed Web of Science ®Google Scholar
• Steiner TJ, Stovner LJ, Katsarava Z, et al. The impact of headache in Europe: principal results of the eurolight project. J Headache Pain. 2014;15:31.
   PubMed Web of Science ®Google Scholar
• Buse DC, Scher AI, Dodick DW, et al. Impact of migraine on the family: perspectives of people with migraine and their spouse/domestic partner in the CaMEO study. Mayo Clin Proc. 2016;91:596–611.
   Web of Science ®Google Scholar
• Macgregor EA, Rosenberg JD, Kurth T. Sex-related differences in epidemiological and clinic-based headache studies. Headache. 2011;51(6):843–859.
   PubMed Web of Science ®Google Scholar
• Nielsen CS, Knudsen GP, Steingrimsdottir OA. Twin studies of pain. Clin Genet. 2012;82(4):331–340.
   PubMed Web of Science ®Google Scholar
• Munakata J, Hazard E, Serrano D, et al. Economic burden of transformed migraine: results from the American migraine prevalence and prevention (AMPP) study. Headache. 2009;49(4):498–508.
   PubMed Web of Science ®Google Scholar
• Kelman L. The triggers or precipitants of the acute migraine attack. Cephalalgia. 2007;27(5):394–402.
   PubMed Web of Science ®Google Scholar
• Silberstein SD. Considerations for management of migraine symptoms in the primary care setting. Postgrad Med. 2016;128(5):523–537.
   PubMed Web of Science ®Google Scholar
• Lipton RB, Dodick D, Sadovsky R, et al. A self-administered screener for migraine in primary care: the ID migraine validation study. Neurology. 2003;61(3):375–382.
   PubMed Web of Science ®Google Scholar
• Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the quality standards subcommittee of the American academy of neurology. Neurology. 2000;55(6):754–762.
   PubMed Web of Science ®Google Scholar
• Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the American headache society evidence assessment of migraine pharmacotherapies. Headache. 2015;55(1):3–20.
   PubMed Web of Science ®Google Scholar
• Migraine: developing drugs for acute treatment [Internet]. Food and Drug Administration; 2018 [cited 2020 Jan 16]. Available from: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/migraine-developing-drugs-acute-treatment
   Google Scholar
• Diener HC, Tassorelli C, Dodick DW, et al. Guidelines of the international headache society for controlled trials of acute treatment of migraine attacks in adults: fourth edition. Cephalalgia. 2019;39(6):687–710.
   PubMed Web of Science ®Google Scholar
• Davies GM, Santanello N, Lipton R. Determinants of patient satisfaction with migraine therapy. Cephalalgia. 2000;20(6):554–560.
   PubMed Web of Science ®Google Scholar
• Lipton RB, Hamelsky SW, Dayno JM. What do patients with migraine want from acute migraine treatment? Headache. 2002;42(Suppl 1):3–9.
   PubMed Web of Science ®Google Scholar
• Mayans L, Walling A. Acute migraine headache: treatment strategies. Am Fam Physician. 2018;97(4):243–251.
   PubMed Web of Science ®Google Scholar
• Cameron C, Kelly S, Hsieh SC, et al. Triptans in the acute treatment of migraine: A systematic review and network meta-analysis. Headache. 2015;55(Suppl 4):221–235.
   PubMed Web of Science ®Google Scholar
• Wendt J, Cady R, Singer R, et al. A randomized, double-blind, placebo-controlled trial of the efficacy and tolerability of a 4-mg dose of subcutaneous sumatriptan for the treatment of acute migraine attacks in adults. Clin Ther. 2006;28(4):517–526.
   PubMed Web of Science ®Google Scholar
• Hepp Z, Dodick DW, Varon SF, et al. Adherence to oral migraine-preventive medications among patients with chronic migraine. Cephalalgia. 2015;35(6):478–488.
   PubMed Web of Science ®Google Scholar
• Oswald JC, Schuster NM. Lasmiditan for the treatment of acute migraine: a review and potential role in clinical practice. J Pain Res. 2018;11:2221–2227.
   PubMed Web of Science ®Google Scholar
• Silberstein SD, Shrewsbury SB, Hoekman J. Dihydroergotamine (DHE) - then and now: a narrative review. Headache. 2020;60(1):40–57.
   PubMed Web of Science ®Google Scholar
• Migranal [package insert]. Bridgewater, NJ: Valeant Pharmaceuticals Pharmaceuticals; 2019.
   Google Scholar
• Nagy AJ, Gandhi S, Bhola R, et al. Intravenous dihydroergotamine for inpatient management of refractory primary headaches. Neurology. 2011;77(20):1827–1832.
   PubMed Web of Science ®Google Scholar
• MacGregor EA, Dowson A, Davies PT. Mouth-dispersible aspirin in the treatment of migraine: a placebo-controlled study. Headache. 2002;42(4):249–255.
   PubMed Web of Science ®Google Scholar
• Codispoti JR, Prior MJ, Fu M, et al. Efficacy of nonprescription doses of ibuprofen for treating migraine headache. a randomized controlled trial. Headache. 2001;41(7):665–679.
   PubMed Web of Science ®Google Scholar
• Vargas BB. Acute treatment of migraine. Continuum (Minneap Minn). 2018;24(4, Headache):1032–1051.
   PubMedGoogle Scholar
• Motrin [package insert]. New York, NY: Pfizer Inc.; 2007.
   Google Scholar
• Ong JJY, De Felice M. Migraine treatment: current acute medications and their potential mechanisms of action. Neurotherapeutics. 2018;15(2):274–290.
   PubMed Web of Science ®Google Scholar
• Coxib and Traditional NSAID Trialists’ (CNT) Collaboration, Bhala N, Emberson J, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382(9894):769–779.
   PubMed Web of Science ®Google Scholar
• Bally M, Dendukuri N, Rich B, et al. Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data. BMJ. 2017;357:j1909.
   PubMed Web of Science ®Google Scholar
• Lipton RB, Stewart WF, Ryan RE Jr., et al. Efficacy and safety of acetaminophen, aspirin, and caffeine in alleviating migraine headache pain: three double-blind, randomized, placebo-controlled trials. Arch Neurol. 1998;55(2):210–217.
   PubMedGoogle Scholar
• Goldstein J, Silberstein SD, Saper JR, et al. Acetaminophen, aspirin, and caffeine in combination versus ibuprofen for acute migraine: results from a multicenter, double-blind, randomized, parallel-group, single-dose, placebo-controlled study. Headache. 2006;46(3):444–453.
   PubMed Web of Science ®Google Scholar
• Langer-Gould AM, Anderson WE, Armstrong MJ, et al. The American academy of neurology’s top five choosing wisely recommendations. Neurology. 2013;81(11):1004–1011.
   PubMed Web of Science ®Google Scholar
• Amin FM, Asghar MS, Hougaard A, et al. Magnetic resonance angiography of intracranial and extracranial arteries in patients with spontaneous migraine without aura: a cross-sectional study. Lancet Neurol. 2013;12(5):454–461.
   PubMed Web of Science ®Google Scholar
• Goadsby PJ. Primary headache disorders: five new things. Neurol Clin Pract. 2019;9(3):233–240.
   PubMedGoogle Scholar
• Curto M, Capi M, Cipolla F, et al. Ubrogepant for the treatment of migraine. Expert Opin Pharmacother. 2020;1–5. doi:10.1080/14656566.2020.1721462.
   Web of Science ®Google Scholar
• Curto M, Cipolla F, Cisale GY, et al. Profiling lasmiditan as a treatment option for migraine. Expert Opin Pharmacother. 2020;21(2):147–153.
   PubMed Web of Science ®Google Scholar
• Giamberardino MA, Affaitati G, Curto M, et al. Anti-CGRP monoclonal antibodies in migraine: current perspectives. Intern Emerg Med. 2016;11(8):1045–1057.
   PubMed Web of Science ®Google Scholar
• Rubio-Beltran E, Labastida-Ramirez A, Villalon CM, et al. Is selective 5-HT1F receptor agonism an entity apart from that of the triptans in antimigraine therapy? Pharmacol Ther. 2018;186:88–97.
   PubMed Web of Science ®Google Scholar
• Raffaelli B, Israel H, Neeb L, et al. The safety and efficacy of the 5-HT 1F receptor agonist lasmiditan in the acute treatment of migraine. Expert Opin Pharmacother. 2017;18(13):1409–1415.
   PubMed Web of Science ®Google Scholar
• Croop R, Goadsby PJ, Stock DA, et al. Efficacy, safety, and tolerability of rimegepant orally disintegrating tablet for the acute treatment of migraine: a randomised, phase 3, double-blind, placebo-controlled trial. Lancet. 2019;394(10200):737–745.
   PubMed Web of Science ®Google Scholar
• Lipton RB, Croop R, Stock EG, et al. Rimegepant, an oral calcitonin gene-related peptide receptor antagonist, for migraine. N Engl J Med. 2019;381(2):142–149.
   PubMed Web of Science ®Google Scholar
• Lipton RB, Dodick DW, Ailani J, et al. Effect of ubrogepant vs placebo on pain and the most bothersome associated symptom in the acute treatment of migraine: the ACHIEVE II randomized clinical trial. JAMA. 2019;322(19):1887–1898.
   PubMed Web of Science ®Google Scholar
• Dodick DW, Lipton RB, Ailani J, et al. Ubrogepant for the treatment of migraine. N Engl J Med. 2019;381(23):2230–2241.
   PubMed Web of Science ®Google Scholar
• Kuca B, Silberstein SD, Wietecha L, et al. Lasmiditan is an effective acute treatment for migraine: a phase 3 randomized study. Neurology. 2018;91(24):e2222–e2232.
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Wietecha LA, Dennehy EB, et al. Phase 3 randomized, placebo-controlled, double-blind study of lasmiditan for acute treatment of migraine. Brain. 2019;142(7):1894–1904.
   PubMed Web of Science ®Google Scholar
• Krege JH, Rizzoli PB, Liffick E, et al. Safety findings from phase 3 lasmiditan studies for acute treatment of migraine: results from SAMURAI and SPARTAN. Cephalalgia. 2019;39(8):957–966.
   PubMed Web of Science ®Google Scholar
• Azzopardi TD, Brooks NA. Oral metoclopramide as an adjunct to analgesics for the outpatient treatment of acute migraine. Ann Pharmacother. 2008;42(3):397–402.
   PubMed Web of Science ®Google Scholar
• Steiner TJ, Jensen R, Katsarava Z, et al. Aids to management of headache disorders in primary care (2nd edition): on behalf of the European headache federation and lifting the burden: the global campaign against headache. J Headache Pain. 2019;20(1):57.
   PubMed Web of Science ®Google Scholar
• Colman I, Brown MD, Innes GD, et al. Parenteral metoclopramide for acute migraine: meta-analysis of randomised controlled trials. BMJ. 2004;329(7479):1369–1373.
   PubMed Web of Science ®Google Scholar
• Kristoffersen ES, Lundqvist C. Medication-overuse headache: epidemiology, diagnosis and treatment. Ther Adv Drug Saf. 2014;5(2):87–99.
   PubMedGoogle Scholar
• Bigal ME, Lipton RB. Overuse of acute migraine medications and migraine chronification. Curr Pain Headache Rep. 2009;13(4):301–307.
   PubMed Web of Science ®Google Scholar
• Reyvow [package insert]. Indianapolis, IN: Eli Lilly & Co.; 2019.
   Google Scholar
• Halker Singh RB, Ailani J, Robbins MS. Neuromodulation for the acute and preventive therapy of migraine and cluster headache. Headache. 2019;59(Suppl 2):33–49.
   PubMed Web of Science ®Google Scholar
• Chou DE, Shnayderman Yugrakh M, Winegarner D, et al. Acute migraine therapy with external trigeminal neurostimulation (ACME): A randomized controlled trial. Cephalalgia. 2019;39(1):3–14.
   PubMed Web of Science ®Google Scholar
• Tassorelli C, Grazzi L, de Tommaso M, et al. Noninvasive vagus nerve stimulation as acute therapy for migraine: the randomized PRESTO study. Neurology. 2018;91(4):e364–e373.
   PubMed Web of Science ®Google Scholar
• Miller S, Sinclair AJ, Davies B, et al. Neurostimulation in the treatment of primary headaches. Pract Neurol. 2016;16(5):362–375.
   PubMedGoogle Scholar
• Rapoport AM, Bonner JH, Lin T, et al. Remote electrical neuromodulation (REN) in the acute treatment of migraine: a comparison with usual care and acute migraine medications. J Headache Pain. 2019;20(1):83.
   PubMed Web of Science ®Google Scholar
• Stokes M, Becker WJ, Lipton RB, et al. Cost of health care among patients with chronic and episodic migraine in Canada and the USA: results from the International burden of migraine study (IBMS). Headache. 2011;51(7):1058–1077.
   PubMed Web of Science ®Google Scholar
• Schwedt TJ. New and emerging treatments for the acute and preventive therapy of migraine and other headaches. Headache. 2019;59(Suppl 2):1–2.
   PubMed Web of Science ®Google Scholar
• Lipton RB, Fanning KM, Serrano D, et al. Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraine. Neurology. 2015;84(7):688–695.
   PubMed Web of Science ®Google Scholar
• O’Flynn N, Ridsdale L. Headache in primary care: how important is diagnosis to management? Br J Gen Pract. 2002;52(480):569–573.
   PubMed Web of Science ®Google Scholar
• What is a headache specialist? Do I need one? And how do I find one? [Internet]. Mount Royal (NJ): American Migraine Foundation; 2017 Jan 05 [cited 2020 Feb 12]. Available from: https://americanmigrainefoundation.org/resource-library/headache-specialist-need-one-find-one/
   Google Scholar